share_log

Precision Optics (OTCMKTS:PEYE) Stock Passes Below Fifty Day Moving Average of $4.34

Defense World ·  Jan 25, 2023 05:21

Precision Optics Co., Inc. (OTCMKTS:PEYE – Get Rating)'s stock price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $4.34 and traded as low as $1.90. Precision Optics shares last traded at $1.95, with a volume of 113,500 shares traded.

Precision Optics Trading Down 1.0 %

The company has a debt-to-equity ratio of 0.23, a current ratio of 1.42 and a quick ratio of 0.76. The business's 50 day moving average is $4.34 and its 200 day moving average is $5.21. The stock has a market cap of $32.98 million, a price-to-earnings ratio of -32.50 and a beta of 0.41.

Precision Optics Company Profile

(Get Rating)

Precision Optics Corporation, Inc designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians.

Featured Articles

  • Get a free copy of the StockNews.com research report on Precision Optics (PEYE)
  • Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
  • How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
  • Is the Pain Over for Baudax Bio Investors after a 70% Spike?
  • Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
  • When Will Crane Holdings Take Flight?

Receive News & Ratings for Precision Optics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Optics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment